Survival in COPD: Impact of lung dysfunction and comorbidities

Medicine (United States)

Volumn 93, Issue 12, 2014, Pages

  Miniati, Massimo ^a   Monti, Simonetta ^b   Pavlickova, Ivana ^b   Bottai, Matteo ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CNR   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; AIRWAY OBSTRUCTION; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC SUSCEPTIBILITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEX; SMOKING; SURVIVAL; CARDIOVASCULAR DISEASE; LONGITUDINAL STUDY; LUNG; LUNG DIFFUSION CAPACITY; METABOLIC DISORDER; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; METABOLIC DISEASES; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84930620243     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000076     Document Type: Article

References (27)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2011. http://www.goldcopd.org. Accessed May 19, 2012.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-773.
3. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-969.
4. Agustí A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012;7:e37483.
5. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155-161.
6. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. A study of the general population. Am J Respir Crit Care Med. 2012;186:975-981.
7. Thomsen M, Dahl M, Lange P, et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:982-988.
8. Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:728-735.
9. Chappell S, Daly L, Morgan K, et al. Cryptic haplotypes of SERPIN A1 confer susceptibility to chronic obstructive pulmonary disease. Hum Mutat. 2006;27:103-109.
10. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of heath status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis. 1992;145:1321-1327.
11. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
12. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720-735.
13. Thurlbeck WM, Müller Emphysema: NL. Emphysema: definition, imaging, and quantification. Am J Roentgenol. 1994;163:1017-1025.
14. Miniati M, Monti S, Basta G, et al. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res. 2011;12:37.
15. Bottai M, Zhang J. Laplace regression with censored data. Biometrical J. 2010;52:487-503.
16. Hernán MA. The hazard of hazard ratios. Epidemiology. 2010;21:13-15.
17. Vestbo J, Anderson W, Coxson HO, et al.; ECLIPSE Investigators. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31:869-873.
18. Fabbri LM, Beghè B, Agustí A. COPD and the solar system. Introducing the chronic obstructive pulmonary disease comorbidome. Am J Respir Crit Care Med. 2012;186:117-119.
19. Iversen KK, Kjaergaard J, Akkan D, et al. ECHOS Lung Function Study Group. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361-369.
20. Iversen KK, Kjaergaard J, Akkan D, et al. ECHOS Lung Function Study Group. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;2:685-691.
21. Johannessen A, Skorge TD, Bottai M, et al. Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med. 2013;187:602-608.
22. Boutou AK, Shrikrishna D, Tanner RJ, et al. Lung function indices for predicting mortality in COPD. Eur Respir J. 2013;42:616-625.
23. Cerveri I, Rossi A, Brusasco V. Look at comorbidities, but don't forget lung function. Am J Respir Crit Care Med. 2013;187: 328-329.
24. Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should be done next. Curr Opin Pulm Med. 2014;20:132-137.
25. Vestbo J, Anderson J, Calverley P, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939-943.
26. Miniati M, Monti S, Bottai M, et al. Forced expiratory volume in one second: prognostic value in systolic heart failure. Int J Cardiol. 2013;168:1573-1574.
27. Miniati M, Monti S, Bottai M, et al. Prognostic value of alveolar volume in systolic heart failure: a prospective observational study. BMC Pulm Med. 2013;13:69.